Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sahai V, et al. Among authors: pisick e. JCO Precis Oncol. 2024 Apr;8:e2300527. doi: 10.1200/PO.23.00527. JCO Precis Oncol. 2024. PMID: 38603652
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Rohatgi N, et al. Among authors: pisick e. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279. JCO Precis Oncol. 2023. PMID: 38039429
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Worden FP, et al. Among authors: pisick e. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16. JCO Precis Oncol. 2024. PMID: 39413339 Clinical Trial.
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies.
Ramisetty S, Subbalakshmi AR, Pareek S, Mirzapoiazova T, Do D, Prabhakar D, Pisick E, Shrestha S, Achuthan S, Bhattacharya S, Malhotra J, Mohanty A, Singhal SS, Salgia R, Kulkarni P. Ramisetty S, et al. Among authors: pisick e. J Clin Med. 2024 Jun 5;13(11):3337. doi: 10.3390/jcm13113337. J Clin Med. 2024. PMID: 38893049 Free PMC article.
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.
Ramisetty S, Kulkarni P, Bhattacharya S, Nam A, Singhal SS, Guo L, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Pisick E, Subbiah S, Rajurkar S, Massarelli E, Salgia R, Mohanty A. Ramisetty S, et al. Among authors: pisick e. J Clin Med. 2023 Jan 11;12(2):599. doi: 10.3390/jcm12020599. J Clin Med. 2023. PMID: 36675528 Free PMC article.
Addressing Drug Resistance in Cancer: A Team Medicine Approach.
Kulkarni P, Mohanty A, Bhattacharya S, Singhal S, Guo L, Ramisetty S, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Gupta N, Kim P, Babikian R, Rajurkar S, Subbiah S, Tan T, Nguyen D, Merla A, Kollimuttathuillam SV, Phillips T, Baik P, Tan B, Vashi P, Shrestha S, Leach B, Garg R, Rich PL, Stewart FM, Pisick E, Salgia R. Kulkarni P, et al. Among authors: pisick e. J Clin Med. 2022 Sep 27;11(19):5701. doi: 10.3390/jcm11195701. J Clin Med. 2022. PMID: 36233569 Free PMC article.
29 results